-
公开(公告)号：US10830678B2
公开(公告)日：2020-11-10
申请号：US15318104
申请日：2015-08-07
摘要： This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.
-
公开(公告)号：US10662464B2
公开(公告)日：2020-05-26
申请号：US15580299
申请日：2016-07-29
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services , American International Biotechnology, LLC
IPC分类号： C12Q1/68 , C12Q1/70 , C12N15/10 , C12N15/70 , C12N15/86 , C40B40/06 , C12Q1/6827 , C12Q1/6806
摘要： Described herein are massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines, including the PVS-RIPO vaccine. The methods allow for the determination of micro-heterogeneity and quantitation of low frequency sequence variants and in the case of PVS-RIPO, are expected to replace the monkey neurovirulence safety test (MNVT) and the mutant analysis by PCR and restriction enzyme cleavage (MAPREC) methods that are currently used to screen lots of RNA virus-derived therapeutics.
-
公开(公告)号：US20190241596A1
公开(公告)日：2019-08-08
申请号：US16312445
申请日：2017-06-28
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Serv
CPC分类号： C07H1/06 , B01J20/103 , B01J20/3204 , B01J20/3246 , B01J20/3251 , C07H1/00 , C07H21/02 , C07H21/04 , C07H23/00
摘要： The invention provides a compound of the formula: and a capture support of the formula: wherein R1, R2, R3, R6, A, B, D, E, J, K, Q, W, and Z are as defined herein. The invention also provides a method of purifying an oligonucleotide or an oligonucleotide analog composed of “b” nucleotides from a mixture comprising the oligonucleotide or oligonucleotide analog and at least one oligonucleotide or oligonucleotide analog composed of “a” nucleotides, wherein b≠a, comprising use of the compound and the capture support.
-
4.发明申请公开(公告)号：US20190016786A1
公开(公告)日：2019-01-17
申请号：US16044083
申请日：2018-07-24
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Serv
发明人： Peter D. Kwong , Gary J. Nabel , Rebecca S. Rudicell , John Mascola , Mark Connors , Ivelin Georgiev , Jiang Zhu , Young Do Kwon , Tongqing Zhou , Yongping Yang , Baoshan Zhang , Gwo-Yu Chuang , Xueling Wu , Zhi-yong Yang , Wei Shi
IPC分类号： C07K16/10 , A61K45/06 , G01N33/569 , A61K39/42 , A61K39/00
摘要： Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
-
公开(公告)号：US20190000781A1
公开(公告)日：2019-01-03
申请号：US16129569
申请日：2018-09-12
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Serv
发明人： Irving W. Wainer , Michel Bernier , Rajib K. Paul
IPC分类号： A61K31/137 , A61K45/06 , A61K31/05
摘要： This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.
-
公开(公告)号：US20180280497A1
公开(公告)日：2018-10-04
申请号：US15758505
申请日：2016-09-09
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Serv , The Chancellor, Masters and Scholars of the University of Oxford
发明人： Robert SEDER , Geoffrey LYNN , Leonard SEYMOUR
CPC分类号： A61K39/39 , A61K47/59 , A61K47/6455 , A61K47/65 , A61K48/0041 , A61K2039/53 , A61K2039/55511 , A61K2039/55555 , A61K2039/6093
摘要： Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.
-
公开(公告)号：US20180273485A1
公开(公告)日：2018-09-27
申请号：US15579123
申请日：2016-06-01
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Serv
发明人： George Kunos , Malliga Iyer , Resat Cinar
IPC分类号： C07D231/06 , C07D401/12 , C07D409/12 , C07D403/12
CPC分类号： C07D231/06 , C07D401/12 , C07D403/12 , C07D409/12
摘要： A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.
-
公开(公告)号：US20180251527A1
公开(公告)日：2018-09-06
申请号：US15982998
申请日：2018-05-17
申请人： THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv , INSTITUTO NACIONAL DE TECNOLOGIA AGROPECUARIA
发明人： Karin Bok , Lorena Laura Garaicoechea , Viviana Parreno , Andrea Pamela Aguilar , Marina Bok , Lisbeth Kim Green , Stanislav Vladimirovich Sosnovtsev
IPC分类号： C07K16/10 , G01N33/569 , A61K39/00
摘要： Isolated VHH monoclonal antibodies are disclosed that specifically bind to a Norovirus polypeptide. In some embodiments, the Norovirus is a Genogroup I Norovirus or a Genogroup II Norovirus. In other embodiments, the Norovirus is Norwalk or MD2004 virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. Also disclosed are methods of treating and/or preventing a NoV infection.
-
公开(公告)号：US20180188254A1
公开(公告)日：2018-07-05
申请号：US15740577
申请日：2016-06-29
申请人： The United States of America, as Represented by the Secretary, Department of Health and Human serv
发明人： Dhaval T. Patel , Kristopher W. Krausz , Frank J. Gonzalez , Electron Kebebew , Matthew Thompson
IPC分类号： G01N33/574 , G01N33/68
CPC分类号： G01N33/57438 , G01N33/6812 , G01N2570/00 , G01N2800/56
摘要： Disclosed herein are methods of diagnosing and treating a malignant adrenocortical tumor, including adrenocortical carcinoma. In some examples, methods of diagnosing a malignant adrenocortical tumor include measuring creatine riboside, L-tryptophan, Nε,Nε,Nε-trimethyl-L-lysine and 3-methylhistidine in a biological sample obtained from a subject with an adrenocortical tumor and identifying an increase in creatine riboside and a decrease in L-tryptophan, Nε,Nε,Nε-trimethyl-L-lysine and 3-methylhistidine in the biological sample when compared to a control or reference value for each molecule indicates a malignant adrenocortical tumor. Methods of treatment and evaluating the effectiveness of an agent for treating a malignant adrenocortical tumor are also disclosed. Additionally, kits, assays and devices for characterizing adrenocortical tumors are provided.
-
公开(公告)号：US20180153978A1
公开(公告)日：2018-06-07
申请号：US15887456
申请日：2018-02-02
申请人： The Board of Regents of the University of Texas System , Yale University , The United States of America, as represented by the Secretary, Department of Health and Human Serv
CPC分类号： A61K39/0011 , A61K48/00 , A61K2039/5152 , A61K2039/5156 , A61K2039/572 , C12N5/0693 , C12N2510/00
摘要： A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.
-
-
-
-
-
-
-
-
-
搜索结果
197 条记录 (耗时 0.039 秒)
